Chicken anti Human Osteopontin c conjugated with FITC

Contact us
Nordic MuBio
Product Code: AhOPNc-F
Product Group: Primary Antibodies
Supplier: Nordic MuBio
CodeSizePrice
AhOPNc-F0.1 mg£473.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Chicken
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Storage:
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles.

Documents

Further Information

Applications Description:
This antibody is suitable for immunohistochemical applications. Optimal working dilutions should be determined for your particular assay conditions.
Caution:
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.?
Concentration:
See vial for concentration.
Formulation:
Phosphate buffered saline, pH 7.2, 50% glycerol with 0.075% sodium azide
Label:
FITC
Product:
Liquid; 0.1 mL
Product Form:
Fluorescein conjugated
Purification Method:
Egg-yolk derived IgY Affinity Purified
Source:
A chicken was immunized with a peptide representing the splice junction of osteopontin-c (Ac-SEEKQNAVSC-COOH). After multiple immunizations, eggs were collected and IgY was purified from the egg yolk. The antibody was affinity purified on an osteopontin-c peptide column and conjugated to fluorescein isothiocyanate.
UniProt:
P10451

References

  • He B, Mirza M, Weber GF., 2006. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25:2192?2202.
  • Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF., 2008. Osteopontin-c is a selective marker of breast cancer. Int J Cancer: 122:2646.
  • Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewicz A, Weber GF, Denhardt DT, Yeo CJ, Arafat HA., 2009. Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery 146:232-40.
  • Tilli, TM, Thuler LC, Matos, AR, Coutinho-Camillo, CM, Soares, FA, da Silva, EA, Neves, AF, Goulart, LR and ER Gimba. 2011.Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp. Mol. Pathol. 92:13-19.
  • Tilli, TM, Mello, KD, Ferreira, LB, Matos, AR, Accioly, MTS, Faria, PAS., Bellahc?ne, A, Castronovo, V and ER Gimba. 2012. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 72:1688-1699.
  • Zhang, MX, Xu YJ, Zhu MC and F. Yan. 2013. Overexpressed Osteopontin-c as a Potential Biomarker for Esophageal Squamous Cell Carcinoma. Asian Pac J Cancer Prev 14: 7315-9
  • T. Martins Tilli, L. Bueon Ferreira and E.R. Pereira Gimba. 2015. Osteopontin-c mediates the upregulation of androgen responsive genes in LNCaP cells through P13K/Akt and androgen receptor signaling. Oncol. Lett. 9: 1845-50.
  • Zduniak K., Ziolkowski, P. Ahlin C., Agrawal, A., Blomqvist, C., Fjallskog, M.L., and G.F. Weber. 2015. Nuclear Osteopontin-c is a prognostic breast cancer marker. Br. J. Cancer 112:729-38.
  • Zduniak, K, Agrawal, A, Agriwal, S, Hossain, MM, Ziolkowski, P and GF Weber, 2016. Osteopontin splice variants are differential predictors of breast cancer treatment responses. BMC Cancer 16:441.